Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine Infusion in Non-Small Cell Lung Cancer Surgery
NCT07347977Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Jan 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial in non-small cell lung cancer (NSCLC) comparing Lidocaine Infusion with Placebo (2 arms). Primary endpoint: Disease-Free Survival at 36 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07347977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347977.